Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of SpringWorks Therapeutics, Inc. to Merck KGaA, Darmstadt, Germany for $47.00 per share in cash is fair to SpringWorks ...

German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around ...

FRANKFURT, April 28 (Bernama-dpa) - German health care and science group Merck has sealed a deal to bolster its cancer ...

Huawei preparing to test latest AI chip to challenge Nvidia (NVDA): report. Merck KGaA to buy Springworks for $3.9 billion.

Merck has moved to strengthen its position in oncology and rare diseases with a $3.9bn agreement to acquire SpringWorks ...

Strategic Acquisition to Expand Oncology Portfolio Deal Overview:German healthcare and materials giant Merck KGaA (NSE: PROR) ...

Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 billion, as the ...

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 ...

DARMSTADT, Germany I April 28, 2025 I Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc.

Merck KGaA agreed to buy SpringWorks Therapeutics Inc., a maker of medicines for cancer and rare diseases, to boost its ...

Merck KGaA acquires SpringWorks Therapeutics for $3.9B to enhance its cancer drug portfolio, boosting revenue growth and ...